Objective To delineate the full phenotypic spectrum and characterize the natural history of limb girdle muscular dystrophy type D1 (LGMDD1). Methods We extracted age at clinical events of interest contributing to LGMDD1 disease burden via a systematic literature and chart review. Manual muscle testing and quantitative dynamometry data were used to estimate annualized rates of change. We also conducted a cross‐sectional observational study using previously validated patient‐reported outcome assessments (ACTIVLIM, PROMIS‐57) and a new LGMDD1 questionnaire. Some individuals underwent repeat ACTIVLIM and LGMDD1 questionnaire assessments at 1.5 and 2.5 years. Results A total of 122 LGMDD1 patients were included from 14 different countries. We identified two new variants (p.E54K, p.V99A). In vitro assays and segregation support their pathogenicity. The mean onset age was 29.7 years. Genotype appears to impact onset age, weakness pattern, and median time to loss of ambulation (34 years). Dysphagia was the most frequent abnormality (51.4%). Deltoids, biceps, grip, iliopsoas, and hamstrings strength decreased by (0.5‐1 lb/year). Cross‐sectional ACTIVLIM and LGMDD1 questionnaire scores correlated with years from disease onset. Longitudinally, only the LGMDD1 questionnaire detected significant progression at both 1.5 and 2.5 years. Treatment trials would require 62 (1.5 years) or 30 (2.5 years) patients to detect a 70% reduction in the progression of the LGMDD1 questionnaire. Interpretation This study is the largest description of LGMDD1 patients to date and highlights potential genotype‐dependent differences that need to be verified prospectively. Future clinical trials will need to account for variability in these key phenotypic features when selecting outcome measures and enrolling patients.
LGMDD2 is due to a transportin-3 defect, involved in HIV nuclear inport, the pathogenetic link is unknown. We determined cytokines by Luminex analysis in plasma from 4 patients carrying mutations of LGMDD2. Two patients are part of an Italian-Spanish family (mutation c.2771delA QVTSAEECKQ VCWALRDFT R LFRCSHSCTV PVTQECLF * ) two are from a family of Hungarian origin, carrying the TPNO3 mutation c.2767delC; each family included an elderly patient and one descendant. Plasma from 4 LGMDD2 patients and 4 health donors were measured in duplicate, using a 1/1 or 1/20 sample dilution. The expression levels of TNFRSF8, IFN-, IL-8/CXCL8 and S100A9 were measured by Multiplex Luminex Assay using two custom-made plates (R&D Systems). Analysis was performed on a Bio-Plex 200 System (Bio-Rad). Statistical analysis was performed with the nonparametric test Mann-Whitney test using GraphPad Prism v9software.Observed concentration was calculated for the cytokines mentioned thorough Bio-Plex 200 system software or by manual interpolation of concentration in the curve. The expression levels of IFNβ were reduced 25 fold (p < 0.005) in patients, while IFN-α increased 2.05 fold. The level of GRO-β was increased 1.65 fold (p < 0.05), in LGMDD2 patients, TNFRSF8 and ICAM-1 were 1.58 fold and 2.15 fold (p < 0.001) enhanced. The levels of S100A8 (p < 0.001) and S100A9 (p < 0.005) were reduced 6 fold and 25-34 fold respectively in LGMDD2 patients compared to control. Expression of IL-1 RI was 2-fold reduced(p < 0.05) in LGMDD2. Age influences expression levels of IL-1 α, MMP10, MMP8 and CXCL5 that gathered in youngest or older patients, independently from family. The genetic mutation that causes the disease makes patients immune to AIDS by unknown mechanism(s), holding promise for research in this field, reassuring patients regarding possible HIV infection. The mutation could block the activity of the HIV-1 intasome, CD3, CD28 peripheral blood cells from transportinopathy patients show lower production of viral proteins in patients than control. The present data demonstrate that the cytokine profile is significantly differentially affected in 4 patients from 2 independent TPNO3 families.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
334 Leonard St
Brooklyn, NY 11211
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.